Legend Biotech to Host Investor Conference Call on First Quarter 2025 Results
Legend Biotech (NASDAQ: LEGN), a global cell therapy leader, has scheduled an investor conference call to discuss its first quarter 2025 financial results. The call will take place on Tuesday, May 13, 2025, at 8:00 am ET.
Key Details:
- Senior leadership will present the company's Q1 2025 performance
- Investors can access the live audio webcast through a provided weblink
- A replay of the webcast and earnings release will be available
- Post-call materials will be accessible through Legend Biotech's Investor Relations website under Events and Presentations
The materials will be made available approximately two hours after the call concludes.
Legend Biotech (NASDAQ: LEGN), leader globale nella terapia cellulare, ha programmato una conference call per gli investitori per discutere i risultati finanziari del primo trimestre 2025. La chiamata si terrà martedì 13 maggio 2025 alle 8:00 ET.
Dettagli principali:
- La dirigenza senior presenterà i risultati del primo trimestre 2025 dell'azienda
- Gli investitori potranno seguire la trasmissione audio in diretta tramite un link fornito
- La registrazione della trasmissione e il comunicato sui risultati saranno disponibili in seguito
- I materiali post-chiamata saranno accessibili sul sito delle Relazioni con gli Investitori di Legend Biotech, nella sezione Eventi e Presentazioni
I materiali saranno disponibili circa due ore dopo la conclusione della chiamata.
Legend Biotech (NASDAQ: LEGN), líder global en terapia celular, ha programado una conferencia telefónica para inversores para discutir los resultados financieros del primer trimestre de 2025. La llamada se realizará el martes 13 de mayo de 2025 a las 8:00 am ET.
Detalles clave:
- La alta dirección presentará el desempeño de la empresa en el primer trimestre de 2025
- Los inversores podrán acceder a la transmisión de audio en vivo mediante un enlace proporcionado
- Estará disponible una repetición de la transmisión y el comunicado de resultados
- Los materiales posteriores a la llamada estarán accesibles en el sitio web de Relaciones con Inversores de Legend Biotech, en la sección de Eventos y Presentaciones
Los materiales estarán disponibles aproximadamente dos horas después de finalizar la llamada.
Legend Biotech (NASDAQ: LEGN), 글로벌 세포 치료 선도 기업이 2025년 1분기 재무 실적을 논의하기 위한 투자자 컨퍼런스 콜을 예정했습니다. 콜은 2025년 5월 13일 화요일 오전 8시 ET에 진행됩니다.
주요 내용:
- 고위 경영진이 2025년 1분기 회사 실적을 발표합니다
- 투자자들은 제공된 웹링크를 통해 라이브 오디오 웹캐스트에 접속할 수 있습니다
- 웹캐스트 녹화 및 실적 발표 자료가 제공됩니다
- 콜 종료 후 자료는 Legend Biotech 투자자 관계 웹사이트의 이벤트 및 프레젠테이션 섹션에서 확인할 수 있습니다
자료는 콜 종료 후 약 2시간 이내에 제공됩니다.
Legend Biotech (NASDAQ : LEGN), leader mondial en thérapie cellulaire, a programmé une conférence téléphonique pour les investisseurs afin de discuter des résultats financiers du premier trimestre 2025. L'appel aura lieu le mardi 13 mai 2025 à 8h00 ET.
Détails clés :
- La direction présentera les performances de l'entreprise au premier trimestre 2025
- Les investisseurs pourront accéder à la diffusion audio en direct via un lien fourni
- Un replay de la diffusion ainsi que le communiqué des résultats seront disponibles
- Les documents post-conférence seront accessibles sur le site des Relations Investisseurs de Legend Biotech, dans la rubrique Événements et Présentations
Les documents seront disponibles environ deux heures après la fin de l'appel.
Legend Biotech (NASDAQ: LEGN), ein weltweit führendes Unternehmen im Bereich Zelltherapie, hat eine Telefonkonferenz für Investoren zur Besprechung der Finanzergebnisse des ersten Quartals 2025 angesetzt. Der Anruf findet am Dienstag, den 13. Mai 2025, um 8:00 Uhr ET statt.
Wichtige Details:
- Die Geschäftsleitung wird die Ergebnisse des ersten Quartals 2025 präsentieren
- Investoren können über einen bereitgestellten Link den Live-Audio-Webcast verfolgen
- Eine Aufzeichnung des Webcasts sowie die Ergebnisveröffentlichung werden verfügbar sein
- Nach der Telefonkonferenz sind die Materialien auf der Investor-Relations-Website von Legend Biotech unter Veranstaltungen und Präsentationen abrufbar
Die Materialien werden etwa zwei Stunden nach Ende der Telefonkonferenz bereitgestellt.
- None.
- None.
SOMERSET, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, May 13, 2025, to review first-quarter 2025 results.
During the webcast and conference call, senior leaders will provide an overview of Legend Biotech’s performance for the quarter.
Investors and other interested parties may join the live audio webcast of the call via this weblink.
A replay of the webcast and earnings news release will be available through the Investor Relations section of Legend Biotech’s website under the Events and Presentations section approximately two hours after the call concludes.
ABOUT LEGEND BIOTECH
With over 2,500 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. The company is at the forefront of the CAR-T cell therapy revolution with CARVYKTI®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the US, Legend is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, the company plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.
Learn more at www.legendbiotech.com, and follow us on X (formerly Twitter) and LinkedIn.
INVESTOR CONTACT:
Jessie Yeung
Tel: (732) 956-8271
jessie.yeung@legendbiotech.com
PRESS CONTACT:
Mary Ann Ondish
Tel: (914) 552-4625
media@legendbiotech.com
FAQ
When is Legend Biotech (LEGN) releasing Q1 2025 earnings?
How can investors join Legend Biotech's Q1 2025 earnings call?
Where can I find Legend Biotech's Q1 2025 earnings replay?
What will be discussed in Legend Biotech's Q1 2025 earnings call?
What time is Legend Biotech's Q1 2025 investor conference call?
